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THROMBOPROPHYLAXIS OF PATIENTS RECEIVING TOTAL HIP 
REPLACEMENT: 1998–2002 VERSUS 2003–2007
Meijer WM1, Overbeek JA1, Woodruff K2, Jackson J3, Penning-van Beest FJA1, 
Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Pﬁzer Inc, 
New York, NY, USA, 3Bristol-Myers Squibb International Corp., Princeton, NJ, USA
OBJECTIVES: To compare initial in-hospital thromboprophylaxis and ﬁrst treatment 
after discharge between 1998–2002 and 2003–2007, among patients receiving total 
hip replacement (THR) in the The Netherlands. METHODS: From the PHARMO 
database, all patients ≥18 years with a THR hospital admission between January 
1998-June 2007 were selected. Patients with in-hospital pharmacy data, referred home 
after discharge, and a follow-up in PHARMO of ≥six months after surgery were 
included in the study cohort. RESULTS: Of the total 6,000 THR patients, 2,106 
(35%) underwent surgery in 1998–2002 and 3,894 (65%) in 2003–2007. About one 
third of all patients were male and mean age was 68 years. Length of hospital stay 
decreased over time: in later years, 52% of THR patients were hospitalized for ≤one 
week compared to 17% of the 1998–2002 patients. Initial in-hospital thrombopro-
phylaxis was mostly with LMWH: 66% of patients in 1998–2002 and 70% in 
2003–2007. After the introduction of fondaparinux in 2003, the proportion of 
patients treated in-hospital with vitamin K antagonists (VKAs) or combination 
LMWH+VKAs decreased (13% to 6% and 18% to 3% respectively). After discharge, 
53% of patients with a THR in 1998–2002 received VKAs and 17% were treated 
with LMWH. In contrast, 44% of patients from 2003–2007 received LMWH and 
only 9% were treated with VKAs at home. The proportion of patients receiving no 
antithrombotic treatment after discharge increased from 30% to 38%. CONCLU-
SIONS: In both ﬁve-year time frames, in-hospital thromboprophylaxis among THR 
patients was mostly with LMWH. First treatment after discharge shifted from primar-
ily VKAs in 1998–2002 to LMWH in 2003–2007. Although guidelines recommend 
thromboprophylaxis for six weeks after surgery, our data show that in later years 
38% of patients did not receive antithrombotic treatment after discharge. With an 
average hospital stay of 8 days, we can therefore assume a six-week treatment period 
is not common practice.
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THE USE OF ALENDRONATE AND CARDIOVASCULAR DISEASES
Lu PY, Hsieh CF, Tsai YW, Huang WF
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OBJECTIVES: We aimed to compare the risk of atrial ﬁbrillation (AF), stroke or acute 
myocardiac infarction (AMI) associated with the use of alendronate and raloxifene. 
We also focused on examining the effect of different dosage forms of alendronate 
(10 mg/daily dose versus 70 mg/weekly dose). METHODS: We used the National 
Health Insurance Research Database for a 8-year population-based retrospective 
cohort study. The study population was those women who ﬁrst took alendronate or 
raloxifene during 2002–2006 and had a history of osteoporosis and vertebral or spinal 
fracture. The outcome measurements include AF, stroke, AMI, or until the end of the 
one-year follow-up period. Cox proportional hazards model was used to control the 
potential confounders. RESULTS: 9,609 women who had been prescribed either 
alendronate (6,494; 72.32%) or raloxifene (2,660; 27.68%) were included. Alendro-
nate users were not at a higher risk of AF (HR 0.60; 95% CI, 0.42–0.85), stroke (HR 
0.47; 95% CI, 0.39–0.57) or AMI (HR 0.51; 95% CI, 0.36–0.72) compared to the 
raloxifene group. When separating the alendronate by different dosage forms, users 
of alendronate 10 mg had a higher risk of AF (HR 1.66 95% CI, 1.12–2.46) and 
stroke (HR 1.56; 95% CL, 1.23–1.98) compared to the raloxifene while the alendro-
nate 70 mg was at a signiﬁcantly lower risk of AF (HR 0.28; 95% CI, 0.18–0.43), 
stroke (HR 0.23; 95% CI, 0.18–0.30) and AMI (HR 0.28, 95% CL, 0.18–0.41). The 
alendronate 70 mg group also demonstrated a lower risk of cardiovascular diseases 
to alendronate 10 mg group in AF, stroke, or AMI with HR of 0.17, 0.16 and 0.21, 
respectively. CONCLUSIONS: Alendronate 10 mg users had a higher risk of AF and 
stroke compared to raloxifene and a higher risk of all three cardiovascular outcomes 
compared to alendronate 70 mg. Further studies are required to investigate this 
relationship.
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TEN-YEAR TRENDS IN STATIN USE AMONG ELDERLY WOMEN
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OBJECTIVES: Recent evidence suggests caution in the use of statins among women 
and the elderly, with some movement towards re-evaluating US guidelines among these 
groups. Therefore, it is important to analyze trends in rates of statin use and patterns 
of subgroup differences over a 10-year period among elderly women. This study 
examines trends and subgroup differences in statin use over 10 years among elderly 
women 65+ years of age using a nationally representative survey. METHODS: Analy-
ses included cross-sectional data (1995–2005) of merged Medicare claims and survey 
data on women Medicare beneﬁciaries from cost and use ﬁles of the Medicare Current 
Beneﬁciary Survey(MCBS). Statin use was identiﬁed from self-reports. Chi-square tests 
and logistic regressions were performed to analyze patterns of statin use. Independent 
variables consisted of demographics, socio-economic status, health, functional status, 
and other risk factors related to cardiovascular morbidity (diabetes, hypertension, 
hyperlipidemia, smoking, and obesity). All analyses accounted for the complex design 
of the MCBS. RESULTS: Overall, 6% in 1995 and 36% in 2005 used statins, a 6-fold 
increase over a period of 10 years. Among those with hyperlipidemia, statin use 
increased from 25% to 55%. Even after controlling for major risk factors such as 
diabetes, hypertension, hyperlipidemia, obesity, and smoking, elderly Latina women 
were less likely to use statins compared to elderly white women. Stain use was more 
likely among elderly women living in urban areas vs. rural areas. While older women 
were less likely to be on statins in 1995, the age differences disappeared in 2005. 
CONCLUSIONS: Statin use has consistently increased over the past decade; among 
those with hyperlipidemia, only 55% remained on statins, suggesting subgroup dif-
ferences in use patterns. Ethnic and rural/urban treatment disparities were evident in 
2005. Further research is needed on the determinants of statin use among elderly 
Latina and rural women.
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REPLACEMENT: 1998–2002 VERSUS 2003–2007
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OBJECTIVES: To compare initial in-hospital thromboprophylaxis and ﬁrst treatment 
after discharge between 1998–2002 and 2003–2007, among patients receiving total 
knee replacement (TKR) in the The Netherlands. METHODS: From the PHARMO 
database, all patients ≥18 years with a TKR hospital admission between January 
1998-June 2007 were selected. Patients with in-hospital pharmacy data, referred home 
after discharge, and a follow-up in PHARMO of ≥six months after surgery were 
included in the study cohort. RESULTS: Of the total 2721 TKR patients, 749 (28%) 
underwent surgery in 1998–2002 and 1972 (72%) in 2003–2007. About 30% of all 
patients were male and mean age was 69 years. Length of hospital stay decreased over 
time: in later years, 44% of TKR patients were hospitalized for ≤one week compared 
to 15% of the 1998–2002 patients. Initial in-hospital thromboprophylaxis was mostly 
with LMWH: 66% of patients in 1998–2002 and 79% in 2003–2007. After the 
introduction of fondaparinux in 2003, the proportion of patients treated in-hospital 
with vitamin K antagonists (VKAs) or combination LMWH+VKAs decreased (14% 
to 6% and 19% to 2% respectively). After discharge, 49% of patients with a TKR in 
1998–2002 received VKAs and 18% were treated with LMWH. In contrast, 52% of 
patients from 2003–2007 received LMWH and only 7% were treated with VKAs at 
home. The proportion of patients receiving no antithrombotic treatment after dis-
charge increased from 34% to 39%. CONCLUSIONS: In both ﬁve-year time frames, 
in-hospital thromboprophylaxis among TKR patients was mostly with LMWH. First 
treatment after discharge shifted from primarily VKAs in 1998–2002 to LMWH in 
2003–2007. Although guidelines recommend thromboprophylaxis for 6 weeks after 
surgery, our data show that in later years 39% of patients did not receive antithrom-
botic treatment after discharge. With an average hospital stay of 9 days we can 
therefore assume a six week treatment period is not common practice.
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TARGETING AFRICAN AMERICANS WITH CONGESTIVE HEART 
FAILURE: THE CASE OF BIDIL
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OBJECTIVES: Previous studies suggest an underuse of evidence based drug therapies 
for chronic disease treatment in for underserved. This study examines utilization pat-
terns for the heart failure drug, BiDil and its generic components, isosorbide dinitrate 
and hydralazine. BiDil was marketed for African Americans as a primary therapy for 
congestive heart failure, a particularly prevalent problem in this population. 
METHODS: The analysis uses a repeated measures ANOVA with data obtained from 
the Center for Medicaid and Medicare Services for 1999–2008. Prescriptions were 
segmented by calendar quarters. Data were extracted using National Drug Codes for 
BiDil and for each generic. State level data were combined by United States Census-
deﬁned regions. The model determined if there are signiﬁcant differences in prescrip-
tion rates controlling for sex, age, race, geographic region, and proportion non-white. 
RESULTS: Approximately 50% of prescriptions for BiDil were from the 17 state 
South region with a 20% African American population. The least number of prescrip-
tions (7%) were from the West region comprising 13 states and 10% African Ameri-
cans. The Northeast and South regions had the earliest BiDil uptake. Isosorbide rates 
showed a steady decline from 1999 to 2008 with no signiﬁcant shift after BiDil’s 
market introduction in July, 2005. Hydralazine use showed a similar pattern. Early 
analysis demonstrated a correlation between geographic region and utilization. Addi-
tional analyses use National Center for Health Statistics ambulatory care survey data 
to assess the signiﬁcance of the regional correlation and the extent to which race and 
other patient factors inﬂuence use of BiDil or its generics. CONCLUSIONS: Demo-
graphic variation suggests differences in prescription rates by racial makeup within 
regions as expected. Overall utilization of BiDil or its generics is low or declining. 
Further research is required to investigate the factors inﬂuencing use of BiDil as a 
heart failure therapy.
